SUPN — Supernus Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.30bn
- $1.93bn
- $718.95m
Supernus Pharmaceuticals Inc expected to post earnings of 68 cents a share - Earnings Preview
Brief: Supernus Enters Into $150 Million Credit Facility
U.S. RESEARCH ROUNDUP-Apollo Endosurgery, Comerica, State Street Corp
Supernus Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Supernus Announces Third Quarter 2022 Financial Results
Supernus Pharmaceuticals Inc expected to post earnings of 36cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Immunic, Novavax, PayPal
U.S. STOCKS ON THE MOVE-Satsuma, defense stocks, Top Ships
Supernus falls after FDA rejects infusion device for Parkinson's disease
Brief: Supernus Pharmaceuticals Provides Regulatory Update On Spn-830
U.S. RESEARCH ROUNDUP-Crowdstrike Holdings, LPL Financial Holdings, Signify Health
Brief: Supernus Announces Second Quarter 2022 Financial Results
Supernus Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Supernus Pharmaceuticals Inc expected to post earnings of 24 cents a share - Earnings Preview
Supernus Pharma rises as FDA approves ADHD treatment for adults
Brief: Supernus Announces FDA Approval Of Qelbree For The Treatment Of ADHD In Adults
Brief: Supernus Announces FDA Approval Of Qelbree For The Treatment Of ADHD In Adults
Supernus Pharmaceuticals Inc expected to post earnings of 24 cents a share - Earnings Preview
Brief: Supernus Reports Final Audited Fourth Quarter And Full Year 2021 Financial Results